Aditxt Appoints Jeffrey Busch as Interim CEO
Aditxt announced the appointment of Jeffrey Busch as Interim Chief Executive Officer of Aditxt, effective May 31, 2026. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision oncology diagnostics subsidiary Ignite Proteomics since March 2026, will now lead the full Aditxt enterprise as it executes an accelerated commercialization strategy centered on Ignite's precision oncology diagnostics platform. Busch simultaneously continues in his role as CEO of Ignite.
